Literature DB >> 24563590

Simultaneous estimation of degree of crystallinity in combination drug product of abacavir, lamivudine and neverapine using X-ray powder diffraction technique.

Pavan Kommavarapu1, Arthanareeswari Maruthapillai1, Ravikiran Allada1, Kamaraj Palanisamy1, Praveen Chappa1.   

Abstract

OBJECTIVE: In the present study, simultaneous determination of degree of crystallinity content in abacavir (ABC), lamivudine (3TC) and neverapine (NVP) from there combination drug product using X-ray powder diffraction (XRPD) technique is developed and validated.
METHODS: The X-ray procedure for the identification and determination of the degree of crystallinity in ABC, 3TC and NVP drug product is developed and validated. It is based on the X-ray diffraction from crystalline region of the drug product. The characteristic peaks of the three drugs were characterized using XRPD.
RESULTS: ABC, 3TC and NVP concentrations ranging from 70% to 130% in drug product were prepared and linearity in this concentration range is described. The % coefficient of variation (%CV) was found to be 0.9982 for ABC, 0.9978 for 3TC and 0.9984 for NVP. The mean recoveries were found to be 100.3% for ABC, 99.0% for 3TC and 100.8% for NVP. Regressions statistics and Analysis of variance (ANOVA) table results were evaluated and found to be satisfactory.
CONCLUSIONS: The method has been applied to unknown mixtures of drug formulations and stability samples. The proposed method can be useful in the quality control of combination drug products.

Entities:  

Keywords:  Analysis of variance; Crystallinity; Drug product; Regressions statistics; X-ray powder diffraction

Year:  2013        PMID: 24563590      PMCID: PMC3930117          DOI: 10.1016/j.jyp.2013.10.003

Source DB:  PubMed          Journal:  J Young Pharm        ISSN: 0975-1483


  8 in total

Review 1.  New anti-HIV agents and targets.

Authors:  Erik De Clercq
Journal:  Med Res Rev       Date:  2002-11       Impact factor: 12.944

Review 2.  How many drug targets are there?

Authors:  John P Overington; Bissan Al-Lazikani; Andrew L Hopkins
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

Review 3.  Drugs, their targets and the nature and number of drug targets.

Authors:  Peter Imming; Christian Sinning; Achim Meyer
Journal:  Nat Rev Drug Discov       Date:  2006-10       Impact factor: 84.694

Review 4.  Molecular mechanisms of drug inhibition of DNA gyrase.

Authors:  R J Lewis; F T Tsai; D B Wigley
Journal:  Bioessays       Date:  1996-08       Impact factor: 4.345

5.  HIV Drug Resistance and the Advent of Integrase Inhibitors.

Authors:  Peter K Quashie; Thibault Mesplède; Mark A Wainberg
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

Review 6.  Initial therapy of HIV infection.

Authors:  Joel E Gallant
Journal:  J Clin Virol       Date:  2002-12       Impact factor: 3.168

7.  A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.

Authors:  Zoe Fox; Ulrik B Dragsted; Jan Gerstoft; Andrew N Phillips; Jesper Kjaer; Lars Mathiesen; Mike Youle; Christine Katlama; Andrew Hill; Johan N Bruun; Nathan Clumeck; Pierre Dellamonica; Jens D Lundgren
Journal:  Antivir Ther       Date:  2006

Review 8.  A review of the pharmacokinetics of abacavir.

Authors:  Geoffrey J Yuen; Steve Weller; Gary E Pakes
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.